Results 41 to 50 of about 2,385,197 (304)
, 2018 PBMC from PTB and IGRA-ve subjects were activated with either PHA or Mtb whole cell lysate. Brefeldin and monensin were added to cultures to prevent cytokine secretion.
Pravat Nalini Sahoo (5770988) +8 more
core +1 more source
C1q-binding anti-HLA antibody assay: A test dilemma
Saudi Journal of Kidney Diseases and Transplantation, 2016 Detection of donor-specific anti-HLA antibodies in patients with kidney graft, or awaiting kidney graft, acts as a predictor for antibody mediated rejection.
Ali H Hajeer
doaj +1 more source
Molecular Oncology, EarlyView.High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira +7 more
wiley +1 more source
Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy
Molecular Oncology, EarlyView.We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley +1 more source
Antibodies, 2022 Serum anti-HLA-I IgG are present in non-alloimmunized males, cancer patients, and transplant recipients. Anti-HLA-I antibodies are also present in intravenous immunoglobulin (IVIg), prepared from the plasma of thousands of healthy donors.
Mepur H. Ravindranath +4 more
doaj +1 more source
Assessment of TWIST1 as an immunotherapeutic target of cancer [PDF]
, 2011 CD8+ T lymphocytes are key mediators of anti-tumour immunity, eliminating tumour cells through the recognition of tumour antigens. Increasing the number of characterised tumour antigens, especially those with highly specific tumour expression, may enable
Poon, E.C.C.
core
Recognition of Human Histocompatibility Leukocyte Antigen (HLA)-E Complexed with HLA Class I Signal Sequence–derived Peptides by D94/NKG2 Confers Protection from Natural Killer Cell–mediated Lysis [PDF]
, 1998 Human histocompatibility leukocyte antigen (HLA)-E is a nonclassical HLA class I molecule, the gene for which is transcribed in most tissues. It has recently been reported that this molecule binds peptides derived from the signal sequence of HLA class I ...
John E. Coligan +14 more
core +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Facioscapulohumeral muscular dystrophy (FSHD) is one of the most debilitating and common muscular dystrophies. Despite its severity, no approved therapy exists for FSHD patients. However, several therapeutic candidates are currently under development, and some have recently entered clinical trials, marking the need for reliable ...
Mustafa Bilal Bayazit +11 more
wiley +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective The prognosis of glioblastoma (GBM) remains highly unfavorable, largely due to high tumor heterogeneity and an immunosuppressive microenvironment. However, the functional role of PANoptosis in this context is poorly understood. Methods Patients were stratified via K‐means clustering. A risk score model was constructed using prognosis‐
Langfei Tian +6 more
wiley +1 more source
Medicina, 2022 Background and Objectives: Testing for anti-human leukocyte antigen (HLA) antibodies both before and after transplantation is of fundamental significance for the success of lung transplantation.
Anita Stanjek-Cichoracka +3 more
doaj +1 more source